“LGMD SPOTLIGHT ON RESEARCH”

 

Researcher:   Antoine Dufour

 

Affiliation:  University of Calgary

 

Role or Position:  Assistant Professor

 

What education and training did you have to arrive at your current position?

 

BA, SUNY Oswego, NY

 

MSc and PhD, Stony Brook University, NY

 

Post-Doctoral fellowship, University of British Columbia, BC, Canada

 

Qu'est-ce qui vous a amené à suivre une carrière dans la recherche et à étudier la dystrophie musculaire en particulier ?

 

2 reasons:

 

1- I study molecular scissors termed proteases and they have multiple functions all aspects of life, biological functions and in diverse muscular dystrophies. Limb-Girdle Muscular Dystrophy type 2A (LGMD2A) is caused by a mutation of one protease termed Calpain-3. I am working on better understanding its functions in muscle biology.

 

2- My older cousin had Duchenne Muscular Dystrophy and I grew up helping him out with various simple tasks he could no longer do as his disease worsens. I was only a kid/teenager (he passed away when I was 14) but that specifically dictated my career choice. I always wanted to become a scientist to characterize defective muscle functions in MDs and better understand how this disease work. After decades of research, there are still many mysteries about MDs and I find that fascinating.

 

Quels sont les sujets que vous étudiez ?

 

I study molecular scissors termed proteases in various disease including muscular dystrophies, arthritis, gastrointestinal diseases and cancer. We use approaches that can detect and track thousands of proteins. This allows us to view disease conditions on a systems level and monitor multiple changes simultaneously. We apply our techniques to characterize Calpain-3 that directly causes LGMD2A when defective.

 

Comment vos travaux aideront-ils les patients ? Sont-ils plutôt de nature scientifique ou pourraient-ils devenir un traitement pour les LGMD ou les médecins en général ?

 

Our work is scientific in nature and will help characterize all the proteins that are changed, affected and causing LGMDs. Despite decades of research, we have a narrow understanding of MDs and our work offers unbiased approaches to track thousands of changes and identify novel drug targets that remain unidentified in context of MDs.

 

Qu'aimeriez-vous que les patients et les autres personnes intéressées par la LGMD sachent à propos de la recherche (vos propres projets et le domaine en général) ?

 

Our work is unbiased meaning we do not start from pre-conceived notions about LGMD. We acquire large amount of data and integrate our results to identify novel interactions within this “web of interactions”. Our work creates the potential for entirely new avenues of exploration and promotes constant innovation over iterative cycles. We develop scientific tools to find a “needle in the haystack” and we will continue finding ways to track down small changes within cells that have profound impact on muscle functions in LGMD patients.

 

Qu'est-ce qui vous incite à continuer à travailler dans ce domaine ?

 

The excitement of finding new interactions that no one else knows about yet and try to fit this new “puzzle piece” within the known networks we currently know about.

 

Comment les patients peuvent-ils vous encourager et vous aider dans votre travail ?

 

Continue raising awareness and communicating to various communities how these diseases affect your daily lives. Social media can be a valuable tool to quickly reach large audiences. For example, the ice bucket challenge to raise awareness for ALS (Amyotrophic lateral sclerosis) was quite successful. It raised significant sums of money for research and offered an opportunity to educate about this disease to the general population.